Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infrared Spectroscopy to Assess Glucokinase Activity and Predict Dorzagliatin Response in Type 2 Diabetes
ChiCTR2500109017Phase 4Not yet recruiting
- Sponsor
- Zhejiang Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dorzagliatin in type 2 diabetes mellitus (T2DM), sponsored by Zhejiang Hospital. Primary endpoints: Blood glucose, Hemoglobin A1c (HbA1c) and 3 more. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500109017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109017.